Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans.
about
GLP-1, the gut-brain, and brain-periphery axesDiabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass.GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons.Lipid-induced peroxidation in the intestine is involved in glucose homeostasis imbalance in miceCardiovascular effects of incretin therapy in diabetes care.Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.Potential role of TCF7L2 gene variants on cardiac sympathetic/parasympathetic activityGlucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism.Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearmEffects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis.Effects of antiretroviral therapy on autonomic function in early HIV infection: a preliminary report.Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized studyThe cardiovascular effects of GLP-1 receptor agonists.Cardiovascular biology of the incretin system.Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.Glucagon-like peptide-1 secretory function as an independent determinant of blood pressure: analysis in the Tanno-Sobetsu study.Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity.Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.Cardiovascular autonomic neuropathies as complications of diabetes mellitus.Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients?Should the sympathetic nervous system be a target to improve cardiometabolic risk in obesity?Mechanisms for the cardiovascular effects of glucagon-like peptide-1.GLP-1 Agonists and Blood Pressure: A Review of the Evidence.Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.The influence of reduced insulin sensitivity via short-term reductions in physical activity on cardiac baroreflex sensitivity during acute hyperglycemia.No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.Direct effect of GLP-1 infusion on endogenous glucose production in humans.The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter.An Increase of Heart Rate and Electrocardiographic Changes after Subcutaneous Liraglutide.Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathyRenal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy menShort-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
P2860
Q27000749-6D0B8A8A-5A23-43A1-BE27-B4F7F633A76FQ30394286-DEE0E3CA-5009-45A7-BD4C-3E1048D65C42Q30497661-EAA0B56B-4C89-46DA-9BA8-A7B7C4C44222Q33940826-156CFE77-43C3-49C8-A11E-26238BE05495Q34171759-48F7C317-1464-4B9E-ABF6-3890E0387DE8Q34269632-6164E979-6B2B-4A6B-8AD5-CDBB2291ACF2Q34410188-5B9C7ABE-CCA1-4E30-AF86-4131E833C85AQ34653078-DD65BE95-D595-44B0-AF80-08142963DBADQ34745109-22DB02D5-7FE1-445C-8622-20235FE224C9Q35026385-23F561DD-4477-49C5-BC2F-1A42EFE23821Q35227453-A95FE29C-4116-4322-AA9F-D09B734A5330Q36134847-B8DA7FF9-C4C2-4CF8-9D17-F2DB5F82CE7BQ36307536-10FC143E-8D0F-4025-927C-233AACE52033Q36368998-DEC06759-8525-4844-92D0-5985F1249F9CQ36484283-66491030-CE96-40FD-881E-F6729F9D1D6BQ36584204-664402B4-F44B-4E70-9D37-F7EF7D20FA83Q36976775-3A5E7FA1-0306-496B-BD8C-7C4DB920879CQ37501257-4118A6A5-840A-4423-9A4D-817AF3BB5798Q37635255-AED2618D-A1E1-4705-9FE7-2201BBE9144FQ37988796-12035746-0989-4B73-B821-3A7999954832Q38128159-20A4CAFC-6228-44EB-82EA-B3F758536739Q38484107-E54E7FC9-7EA2-4C38-BE0A-085B1EB42338Q38589032-1A056ABE-34B8-48B4-8AC6-6B19A7871F1CQ38709406-2A4FB48F-B03A-4131-BADD-CC57DC3B0CBBQ39220482-28743067-C645-40AC-8538-302E2C60F369Q40425449-8F9E7B9A-1A14-4DD0-A2E9-0820158BE840Q46191665-1D319BBD-0DCB-433A-A472-64466612D9CAQ46637270-6302D696-1648-4F0E-9F2E-165E3BC94943Q46833674-1EF651B9-06C0-41C6-B106-FF0B3FFBBF76Q46906226-4CB594E0-FC94-4590-B09F-9B5E3F97884DQ48486475-80B02085-4AE9-4878-889E-27DFAB6FF5E0Q49316193-83033F86-10BC-41C1-B04A-29DEA1ED99A7Q51017631-17107618-33F2-4EC1-8765-3A4349531794Q58167256-C1121D6F-6561-4DFA-8853-2D65DC7273C8Q58167460-B7F6E563-7102-4D0B-9146-00CE419DF048Q58447382-6D05A706-EBA4-45C0-9F66-3774BFC3BD74
P2860
Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Effects of glucagon-like pepti ...... ympathetic activity in humans.
@en
type
label
Effects of glucagon-like pepti ...... ympathetic activity in humans.
@en
prefLabel
Effects of glucagon-like pepti ...... ympathetic activity in humans.
@en
P2093
P2860
P50
P1476
Effects of glucagon-like pepti ...... ympathetic activity in humans.
@en
P2093
Christopher N Andrews
David Sletten
Nisha Charkoudian
Phillip A Low
P2860
P304
P356
10.1152/AJPREGU.00153.2008
P577
2008-07-02T00:00:00Z